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ABSTRACT
Long non-coding RNAs (lncRNAs) play key roles in
cancer and are at the vanguard of precision thera-
peutic development. These efforts depend on large
and high-confidence collections of cancer lncR-
NAs. Here, we present the Cancer LncRNA Cen-
sus 2 (CLC2). With 492 cancer lncRNAs, CLC2 is
4-fold greater in size than its predecessor, with-
out compromising on strict criteria of confident
functional/genetic roles and inclusion in the GEN-
CODE annotation scheme. This increase was en-
abled by leveraging high-throughput transposon in-
sertional mutagenesis screening data, yielding 92
novel cancer lncRNAs. CLC2 makes a valuable ad-
dition to existing collections: it is amongst the
largest, contains numerous unique genes (not found
in other databases) and carries functional labels
(oncogene/tumour suppressor). Analysis of this
dataset reveals that cancer lncRNAs are impacted by
germline variants, somatic mutations and changes
in expression consistent with inferred disease func-
tions. Furthermore, we show how clinical/genomic
features can be used to vet prospective gene sets
from high-throughput sources. The combination of
size and quality makes CLC2 a foundation for preci-
sion medicine, demonstrating cancer lncRNAs’ evo-
lutionary and clinical significance.
GRAPHICAL ABSTRACT
INTRODUCTION
Tumours arise and grow via genetic and non-genetic
changes that give rise to widespread alterations in gene
expression programmes (1–3). The numerous dysregulated
genes may encode classical protein-coding mRNAs or non-
protein coding RNAs, but it is likely that just a subset of
these actually functionally contribute to pathogenic cellu-
lar hallmarks. The identification of such functional cancer
genes is critical for the development of targeted cancer ther-
apies, as well as emerging methods to identify additional
cancer genes. For protein-coding genes (pc-genes), datasets
such as the Cancer Gene Census (CGC) collect and orga-
nize comprehensive gene collections according to defined
criteria, and has proven invaluable for scientific research
and drug discovery (4).
The past decade has witnessed the discovery of numer-
ous non-protein-coding RNA genes in mammalian cells
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(5,6). The most numerous but poorly understood produce
long non-coding RNAs (lncRNAs), defined as transcripts
>200 nt in length with no detectable protein-coding poten-
tial (7). Although their molecular mechanisms are highly
diverse, many lncRNAs have been shown to interact with
other RNA molecules, proteins and DNA by structural
and sequence-specific interactions (8,9). Most lncRNAs are
clade- and species-specific, but a subset display deeper evo-
lutionary conservation in their gene structure (10) and a
handful have been demonstrated to have functions that were
conserved across millions of years of evolution (10,11). The
numbers of known lncRNA genes in human have grown
rapidly, and present catalogues range from 18 000 to ∼100
000 (12); however just a tiny fraction have been function-
ally characterized (13–16). As lncRNAs likely represent
a huge yet poorly understood component of cellular net-
works, understanding the clinical and therapeutic signifi-
cance of these numerous novel genes is a key contemporary
challenge.
LncRNAs have been implicated in molecular processes
governing tumorigenesis (17). LncRNAs may promote or
oppose cancer hallmarks (18). This fact, coupled to the
emergence of potent in vivo inhibitors in the form of an-
tisense oligonucleotides (ASOs) (19), has given rise to seri-
ous interest in lncRNAs as drug targets in cancer by both
academia and pharma (17,20–22).
Initially, cancer lncRNAs were discovered by classi-
cal functional genomics workflows employing microarray
or RNA-seq expression profiling (23,24). More recently,
CRISPR-based functional screening (25) and bioinformatic
predictions (26–28) have also emerged as powerful tools for
novel cancer gene discovery. To assess their accuracy, these
approaches require accurate benchmarks in the form of cu-
rated databases of known cancer lncRNAs.
Any discussion of lncRNAs and cancer requires careful
terminology. Experimental evidence suggest that for some
lncRNAs, it is a DNA element within the gene, in addi-
tion to or instead of the RNA transcript, which mediates
downstream gene regulation (29–31). This introduces the
need for meticulous assessment of the basis of each lncRNA
gene’s functionality. Furthermore, it has been shown that
lncRNAs can exert strong phenotypic effects in one cell
background, but none in another (32). In the context of tu-
mours, this means that amongst the large numbers of differ-
entially expressed lncRNAs (24), just a fraction is likely to
functionally contribute to a relevant cellular phenotype or
cancer hallmark (20,33–36). Such genes, termed here ‘func-
tional cancer lncRNAs’, are the focus of this study. Remain-
ing changing genes are non-functional ‘bystanders’, that are
largely irrelevant in understanding or inhibiting the molec-
ular processes causing cancer and highlight the importance
of not assessing functionality evidence simply by expres-
sional changes.
There are a number of excellent databases of cancer-
associated lncRNAs: lncRNADisease (37), CRlncRNA
(38), EVLncRNAs (39) and Lnc2Cancer 3.0 (40). These
principally employ labour-intensive manual curation, and
rely extensively on differential expression to identify can-
didates. On the other hand, these databases have not yet
taken advantage of recent high-confidence sources of func-
tional cancer lncRNAs, such as high-throughput functional
screens (25,41). For these reasons, existing annotations
likely contain unknown numbers of bystander lncRNAs,
whilst omitting large numbers of bona fide functional can-
cer lncRNAs. Thus, studies requiring high-confidence gene
sets, including benchmarking or drug discovery, call for a
database focussed exclusively on functional cancer lncR-
NAs.
Here, we address this need through the creation of the
Cancer LncRNA Census 2 (CLC2). It not only extends our
previous CLC dataset by several fold (42), but more impor-
tantly, CLC2 takes a major step forward methodologically,
by implementing an automated curation component that
utilizes functional evolutionary conservation for the first
time. Using these data, we present a comprehensive analysis
of the genomic and clinical features of cancer lncRNAs.
MATERIALS AND METHODS
Gene curation
If not stated otherwise, GENCODE v28 gene IDs (gen-
code.v28.annotation.gtf) were used.
Literature search
PubMed was searched for publications linking lncRNA
and cancer using keywords: long noncoding RNA cancer,
lncRNA cancer. Additional inclusion criteria consisted of
GENCODE annotation, reported cancer subtype and can-
cer functionality (oncogene/tumour suppressor). The man-
ual curation and assigning evidence levels to each lncRNA
was performed exactly as previously (42) and included re-
ports until December 2018.
CLIO-TIM
From the CCGD website (http://ccgd-starrlab.oit.umn.edu/
about.php, May 2018 (41)) a table with all CIS elements was
downloaded. These mouse genomic regions (mm10) were
converted to homologous regions in the human genome
assembly hg38 using the LiftOver tool (https://genome.
ucsc.edu/cgi-bin/hgLiftOver). Settings: original Genome
was Mouse GRCm38/mm10 to New Genome Human
GRCh38/hg38, minMatch was 0.1 and minBlocks 0.1. For
insertion sites intersecting several lncRNA genes, all the
genes were reported. IntersectBed from bedtools was used
to align human insertion sites to GENCODE IDs by in-
tersecting at least 1 nt and assigned to protein-coding or
lncRNA gene families. Insertion sites aligning to protein-
coding and lncRNA genes were always assigned to pc-genes.
If insertion sites overlap multiple ENSGs, all genes are re-
ported. Insertion sites not aligning to protein-coding or
lncRNAs genes were added to the intergenic region.
CCGD human Entrez gene results were converted to
GENCODE IDs using the ‘Entrez gene ids’ Metadata
file from https://www.gencodegenes.org/human/ to com-
pare CLIO-TIM results with CCGD results for each gene
set.
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MiTranscriptome data for evaluating intergenic insertion
sites
The cancer associated MiTranscriptome IDs (24) previously
used in Bergada et al. (43) were intersected with intergenic
insertion sites using IntersectBed. With ShuffleBed the in-
tergenic insertions were randomly shuffled 1000× and as-
signed to MiTranscriptome IDs.
CRISPRi
We used the Supplementary Table S1 from the 2017 Liu et
al. paper (44) to extract ENST IDs and gene names which
are then converted to GENCODE IDs to match each guide
(LH identifier in the screen). From Supplementary Table S4
from the 2017 Liu et al. paper (Liu et al aah7111-TableS4)
(44), we extracted genes with ‘hit’ (validated as a hit in the
screen), ‘LH’ (unique identifiers correlating to a gene in the
screen) and ‘lncRNA’ (referring to a lncRNA gene and to
exclude lncRNA hits close to a pc-gene (‘Neighbor hit’)) re-
sulting in 499 hits. Of these, 322 hits contain a GENCODE
IDs and were used for enrichment analysis, tested by one-
sided Fisher’s test.
We included n = 21 CRISPRi genes to the CLC2 from
the Supplementary Figure S8A from the 2017 Liu et al.
paper (44), the tested cancer cell line and the effect of the
CRISPRi on the growth phenotype (either promoting (tu-
mor suppressor) or inhibiting (oncogene)) of each lncRNA
was reported.
Cancer gene sets
For downstream analysis protein-coding (pc) genes (GEN-
CODE IDs) are grouped in cancer-associated pc-genes
(CGC genes) and non-cancer-associated pc-genes (non-
CGC n = 19 174). The TSV file containing the CGC data
was downloaded from https://cancer.sanger.ac.uk/census
with 700 ENSGs with 698 ENSG IDs detected in GEN-
CODE v28 of which 696 are unique (CGC n = 696). The
same is done for lncRNAs, into CLC2 (n = 492) and non-
CLC genes (n = 15 314).
Matched expression analysis
Based on an in-house script used for Survival analy-
sis (section below), TCGA survival expression data for
each GENCODE ID are reported and the average FPKM
across all tumor samples is calculated. The count distribu-
tion of non-CGC and non-CLC gene expression to CGC




The default CPAT settings (http://lilab.research.bcm.edu/
cpat/) were used to assess lncRNA transcripts; the coding
probability for human transcripts ≥0.364 indicates coding
sequences (http://rna-cpat.sourceforge.net) and the com-
parisons are tested using one-sided Fisher’s test.
Cancer lncRNA databases
The tested databases were first filtered for lncRNAs in the
GENCODE v28 long non-coding annotation (n = 15 767).
Lnc2cancer 3.0 GENCODE IDs from the datatable
(http://www.bio-bigdata.com/lnc2cancer/download.html)
were evaluated (n = 688) (40).
CRlncRNA gene names from (http://crlnc.xtbg.ac.cn/
download/) were converted to GENCODE IDs (n = 146)
(38).
EVlncRNAs gene names (http://biophy.dzu.edu.cn/
EVLncRNAs/) were converted to GENCODE IDs (n =
187) (39).
lncRNADisease gene names from (http://www.rnanut.
net/lncrnadisease/index.php/home/info/download) and
only cancer-associated transcripts (carcinoma, lymphoma,
cancer, leukemia, tumor, glioma, sarcoma, blastoma,
astrocytoma, melanoma and meningioma) were extracted.
Names were converted to GENCODE IDs (n = 137) (37).
Features of CLC2 genes
Genomic classification. The genomic classifi-
cation was performed as previously (42) us-
ing an in house script (https://github.com/gold-
lab/shared scripts/tree/master/lncRNA.annotator).
This analysis uses lncRNA on transcript level and protein
coding genes on gene level (default settings).
Genomic classification of CLC2 to CGC/non-CGC genes.
Genomic locations were compared using IntersectBed from
bedtools (default settings). This analysis was performed on
gene level.
Small RNA analysis. For this analysis ‘snoRNA’,
‘snRNA’, ‘miRNA’ and ‘miscRNA’ coordinates were
extracted from GENCODE v28 annotation file and inter-
sected with the genomic region of the genes (intronic and
exonic regions).
Repeat elements. In total 452 CLC2 lncRNAs were com-
pared to 1693 expression-matched non-CLC lncRNAs
using the LnCompare Categorical analysis (http://www.
rnanut.net/lncompare/) (45).
Feature analysis. In total 452 CLC2 lncRNAs and 120
mutagenesis lncRNAs were compared to the GENCODE
v24 reference using LnCompare (http://www.rnanut.net/
lncompare/) (45).
Cancer characteristic analysis
Differential gene expression analysis (DEA). Differen-
tial gene expression analysis (DEA) was performed using
TCGA data and TCGAbiolinks. Analysis was performed
as reported in manual for matching tumour and normal tis-
sue samples using the HTseq analysis pipeline as described
previously (https://www.bioconductor.org/packages/devel/
bioc/vignettes/TCGAbiolinks/inst/doc/analysis.html) (46).
For this analysis, only matched samples were used and the
TCGA data were presorted for tumour tissue samples (TP
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with 01 in sample name) and solid tissue normal (NT with
11 in sample name). Settings used for DEA analysis: fdr.cut
= 0.05, logFC.cut = 1 for DGE output between matched
TP and NT samples for 20 cancer types. CLC2 cancer types
had to be converted to TCGA cancer types (Supplemen-
tary Figure S6A). Cancer types and number of samples
used in the analysis can be found in Supplementary Fig-
ure S6B. DEA enrichment analysis tested with one-sided
Fisher’s test. For each CLC2 gene reported as true oncogene
(n = 275) or tumour suppressor (n = 95), hence where no
double function is reported (n = 22), the positive and neg-
ative fold change (FC) values were counted and compared
to expression-matched lncRNA genes found in the DEA.
Survival analysis. An in-house script for extracting TCGA
survival data was used to generate P-values correlating
to survival for each gene. Expression and clinical data
from 33 cohorts from TCGA with the ‘TCGAbiolinks’
R package (https://bioconductor.org/packages/release/
bioc/html/TCGAbiolinks.html) were downloaded (46).
P-value and Hazard ratio were calculated with the Cox
proportional hazards regression model from ‘Survival’
R package (https://cran.r-project.org/web/packages/
survival/survival.pdf). All scripts were adapted from here
(https://www.biostars.org/p/153013/) and are available
upon request. For downstream analysis, only groups with
at least 20 patient samples in high or low expression group
were used. The plot comprises only the most significant
cancer survival P-value per gene and was assessed by the
Komnogorow–Smirnow test (ks test).
Cancer-associated SNP analysis. SNP data linked to
tumour/cancer were extracted from the genome-wide asso-
ciation studies (GWAS) page (https://www.ebi.ac.uk/gwas/
docs/file-downloads) (n = 5331) and intersected with the
whole exon body of the genes. SNPs were intersected to the
transcript bed file and plotted per nt in each subset (SNP/nt
y-axis) and tested using one-sided Fisher’s test.
Conservation analysis. Whole exon body of the genes
used in the SNP analysis were evaluated using Phast-
Cons Scores (phastCons100way.UCSC.hg38) and the R
package ‘GenomicScores’ (https://www.bioconductor.org/
packages/release/bioc/html/GenomicScores.html). Conser-
vation scores for CLC2 SNP exons were plotted and
compared to the mean of all CLC2 exons and non-
CLC2matched exons, tested using one-sided Fisher’s test.
CNV analysis. Human CNV in lncRNAs downloaded
from http://bioinfo.ibp.ac.cn/LncVar/download.php (47).
NONCODE IDs were converted to GENCODE IDs using
NONCODEv5 hg38.lncAndGene.bed.gz. CLC2 and non-
CLC ENSGs were matched to NONHSAT IDs with a sig-
nificant P-value (0.05, n = 733) in the LncVAR table and
tested using one-sided Fisher’s test.
Code availability. Custom code are available from the cor-
responding author upon request.
In vitro validation
Cell culture. HeLa cells were cultured on Dulbecco’s Mod-
ified Eagles Medium (DMEM) (Sigma-Aldrich, D5671)
supplemented with 10% fetal bovine serum (FBS) (Ther-
moFisher Scientific, 10500064), 1% L-Glutamine (Ther-
moFisher Scientific, 25030024), 1% Penicillin-Streptomycin
(ThermoFisher Scientific, 15140122). Cells were grown at
37◦C and 5% CO2 and passaged every 2 days at 1:5 dilu-
tion.
Generation of Cas9 stable cell lines. HeLa cells were trans-
duced at a high multiplicity of infection with infection me-
dia composed by: lentivirus carrying the Cas9-BFP vector
(Addgene 52962) and Hexadimethrine bromide (8 g/ml,
Sigma-Aldrich 107689) resuspended in DMEM (10% FBS,
1% L-glutamine). Cells were incubated in infection media
during 48 h. After that, the infection media was replaced
by selective media composed by complete DMEM (10%
FBS, 1% L-Glutamine and 1% Penicillin-Streptomycin) and
Blasticidin (4 g/ml, Sigma-Aldrich 15205). Cells were se-
lected until control cells were completely dead. Finally, cells
were sorted twice selecting BFP positive cells by fluores-
cence activated cell sorting and expanded.
CRISPR inhibition sgRNA pair design and cloning.
sgRNA pairs targeting LINC00570 were designed using
GPP sgRNA designer (https://portals.broadinstitute.org/
gpp/). The sgRNA pairs were manually selected from
the output list and cloned into the pGECKO backbone
(CRISPRi.1: 5′ GTTACTTCCAACGTACCATG 3′,
CRISPRi.2: 5′ CCTGTACCCCCATGGTACGT 3′)
(Addgene 78534; (48))
Antisense LNA GapmeR design. Antisense LNA Gap-
meR Control (5′ AACACGTCTATACGC 3′) and three
Antisense LNA GapmeR Standard targeting LINC00570
(LNA1: 5′ GGAAATTGCTCTGATG 3′, LNA2: 5′ GATT
GGCATTGGGATA 3′, LNA3: 5′ GAAGTGGCCTGAGA
AA 3′) were designed and purchased at Qiagen.
RT-qPCR. For each time point total RNA was extracted
(Zymo Research, R1055) and reverse transcribed (Promega,
A5000). Transcript levels of LINC00570 (FP: 5′ TAGGAG
TGCTGGAGACTGAG 3′, RP: 5′ GTCGCCATCTTGGT
TGTCTG 3′), ROCK2 (Sigma KSPQ12012, sequence un-
known) and housekeeping genes HPRT1 (FP: 5′ ATGA
CCAGTCAACAGGGGACAT 3′, RP: 5′ CAACACTTCG
TGGGGTCCTTTTCA 3′) and GAPDH (FP: 5′ GCAC
CGTCAAGGCTGAGAAC 3′, RP: 5′ TGGTGAAGAC
GCCAGTGGA 3′) were measured using GoTaq qPCR
Master Mix (Promega, A6002) on a TaqMan Viia 7 Real-
Time PCR System. Data were normalized using the Ct
method (49)).
TOPO Cloning and Sanger sequencing of the qPCR am-
plicon. The qPCR product of LINC00570 amplified us-
ing Qiagen QuantiNova RT (Qiagen, 205410) and Quanti-
Nova SYBR Green PCR Kit (Qiagen, 208052) was run on
a 2% agarose gel. The main band (corresponding to the ex-
pected amplicon size of 95 bp) was purified using the Gene-
JET Gel Extraction and DNA Cleanup Micro Kit (Thermo
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Fisher Scientific, K0831). Using the TOPO TA Cloning
Kit (Thermo Fisher Scientific, 45–0030), 4 l of the puri-
fied amplicon were ligated into the TOPO backbone vector.
A total of 2 l of ligation product was used to transform
Stbl3 competent cells, bacterial colonies were expanded and
Sanger sequencing was performed (MicroSynth GmBH) us-
ing the M13 forward primer targeting the backbone pro-
vided with the TOPO TA Kit.
Viability assay. HeLa cells (n = 4 biological replicates)
were transfected with Antisense LNA GapmeRs at a con-
centration of 50nM based on manufacturer’s recommen-
dation (Qiagen) using Lipofectamine 2000 (Thermofisher,
11668019) according to manufacturer’s protocol. One day
after, transfected cells were plated in a white, flat 96-well
plate (3000 cells/well) (Corning CLS3610). Viability was
measured in technical replicates using CellTiter-Glo 2D Kit
(Promega G9241) following manufacturer’s recommenda-
tions at 0, 24, 48, 72 h after seeding. Luminescence was
detected with Tecan Reader Infinite 200. Statistical signif-
icance calculated by t-test.
For CRISPR inhibition experiments (n = 4), HeLa-Cas9
cells were transfected with control sgRNA plasmid and two
LINC00570 targeting plasmids using Lipofectamine 2000
(Thermofisher, 11668019) according to manufacturer’s pro-
tocol. Cells were selected with Puromycin (2 g/ml, Sigma-
Aldrich P7255) for 48 h. Viability assay was performed as
previously described.
RESULTS
Integrative, semi-automated cataloguing of cancer lncRNAs
We sought to develop an improved map of lncRNAs with
functional roles in either promoting or opposing cancer
hallmarks or tumourigenesis. Such a map should prioritize
lncRNAs with genuine causative roles, and exclude false-
positive ‘bystanders’––genes whose expression changes but
play no functional role.
We began with conventional manual curation of lncR-
NAs from the scientific literature, covering the period from
January 2017 (directly after the end of the first CLC (42)) to
the end of December 2018. We continued to use stringent
criteria for defining cancer lncRNAs––genes must be anno-
tated in GENCODE (here version 28), and cancer function
must be demonstrated either by functional in vitro or in vivo
experiments, or germline or somatic mutational evidence
(see ‘Materials and Methods’ section) (Figure 1A). Alto-
gether we collected 253 novel lncRNAs in this way, which
added to the original CLC amounts to 375 lncRNAs, here-
after denoted as ‘literature lncRNAs’ (Figure 1A).
We recently showed that some literature-curated lncR-
NAs were also targeted by previously overlooked mutations
in published transposon insertional mutagenesis (TIM)
screens (42). We hypothesized that this insight could be ex-
tended to identify novel functional cancer lncRNAs. Thus
we developed a pipeline to automatically identify human
lncRNAs by orthology to a collection of TIM hits in mouse
(41). In this way 123 lncRNAs were detected, of which 102
were not already in the literature set. These were added to
the CLC2, henceforth denoted as ‘mutagenesis lncRNAs’
(Figure 1B). This analysis is discussed in more detail in the
next section.
Pooled functional screens based on CRISPR-Cas9 loss-
of-function have recently emerged as a powerful means of
identifying function cancer lncRNAs (25). However, there
has been relatively little validation of the hits from such
screens, and it is possible that they contain substantial
false positives (50,51). Amongst the few datasets presently
available, the most comprehensive comes from a CRISPR-
inhibition (CRISPRi) screen of ∼16 000 lncRNAs in seven
human cell lines, with proliferation as a readout (44). Of
the 499 hits identified, 322 are annotated by GENCODE
and hence could potentially be included in CLC2. These are
moderately enriched for known cancer lncRNAs from the
literature search (Figure 1C). That study independently val-
idated 21 GENCODE-annotated hits, of which four (19%)
were already mentioned in the literature, and two (10%)
were detected by TIM above. Given the uncertainty over
the true-positive rates of unvalidated screen hits, we opted
for a conservative approach and included the remaining 15
novel and independently validated lncRNAs from this study
(‘CRISPRi lncRNAs’) (Figure 1C).
Altogether, the resulting CLC2 set comprises 492 unique
lncRNA genes, representing a 4.0-fold increase over its pre-
decessor. The entire CLC2 dataset is available in Supple-
mentary Table S1 and S2. Importantly, the dataset is fully
annotated with evidence information, affording users com-
plete control over the particular subsets of lncRNAs (liter-
ature, mutagenesis and CRISPRi) that they wish to include
in their analyses.
Automated annotation of human cancer lncRNAs via func-
tional conservation
We recently showed that transposon insertional mutage-
nesis (TIM) screens identify cancer lncRNAs in mouse
(42,52), and that some of these overlapped previously
known human cancer lncRNAs (Figure 2A). TIM screens
identify ‘common insertion sites’ (CIS), where multiple
transposon insertions at a particular genomic location have
given rise to a tumour, thereby implicating the underlying
gene as an oncogene or tumour suppressor.
Here, we extend this strategy to identify new func-
tional cancer lncRNAs, by developing a new pipeline called
CLIO-TIM (cancer lncRNA identification by orthology
to TIM). Briefly, CLIO-TIM uses chain alignments (53)
to map mouse CIS to orthologous regions of the human
genome, and then identifies the most likely gene target (see
‘Materials and Methods’ section) (Figure 2B) (Supplemen-
tary Figure S1B). Available CIS maps are based on a variety
of identification methods, resulting in CIS with a range of
sizes, from 1 bp upwards. We opted to remove our previ-
ously conservative size criterion (CIS = 1 bp), to now con-
sider elements of any size resulting in 26 345 CIS (compared
to 2806 previously (42)) (Supplementary Figure S1A). This
yields a 3-fold increase in sensitivity for true-positive CGC
genes (72% compared to 26.4% previously (42)) (Supple-
mentary Figure S1D).
Based on this expanded dataset, CLIO-TIM identified 16
430 orthologous regions in human (hCIS) (Figure 2B) (Sup-
plementary Figure S1A). Altogether, 123 lncRNAs and
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Figure 1. Functional cancer lncRNAs from three sources are integrated in the CLC2. CLC2 only contains lncRNAs annotated by GENCODE. (A)
Literature curation with four criteria are used to define ‘literature lncRNAs’. ‘Literature 2017/2018’ indicates curated genes from the original CLC and
newly annotated in CLC2, respectively. (B) Transposon insertional mutagenesis screens identify ‘mutagenesis lncRNAs’. (C) Validated hits from CRISPRi
proliferation screens are denoted ‘CRISPRi lncRNAs’. ‘non-CLC’ denotes annotated lncRNAs that are not associated with cancer by literature search.
Statistical significance calculated by one-sided Fisher’s test.
9295 pc-genes were identified as potential cancer genes. It
should be noted that the locations of originating mutations
within CIS regions remains imprecisely known, meaning
that we cannot say with certainty which mutations fall in
gene exons or introns. An example is the human-mouse or-
thologous lncRNA locus shown in Figure 2B, comprising
Gm36495 in mouse and LINC00570 in human. A CIS lies
upstream of the mouse gene’s TSS, mapping to the first in-
tron of the human orthologue. LINC00570 is an alterna-
tive identifier for ncRNA-a5 cis-acting lncRNA identified
by Orom et al. (54), that has not previously been associated
with cancer or cell growth.
We expected that hCIS regions are enriched in known
cancer genes. Consistent with this, the 698 pc-genes from the
COSMIC CGC (4) (red in Supplementary Figure S1D) are
155-fold enriched with hCIS over intergenic regions (light
grey). Turning to lncRNAs, the 375 literature lncRNAs are
19.5-fold enriched, supporting their disease relevance (Fig-
ure 2C). Thus, CLIO-TIM predictions are enriched in gen-
uine protein-coding and lncRNA functional cancer genes.
Supporting its accuracy, the overall numbers of genes im-
plicated by CLIO-TIM agree with independent analysis in
the CCGD database (Supplementary Figure S1C).
An additional 209 hCIS fall in intergenic regions that
are neither part of pc-genes or lncRNAs, leading us to
ask whether some may affect lncRNAs that are not anno-
tated by GENCODE (Figure 2C). To test this, we utilized
the large set of cancer-associated lncRNAs from miTran-
scriptome (24). A total of 186 hCIS intersect 2167 miTran-
scriptome transcripts, making these potentially novel non-
annotated transcripts involved in cancer. Nevertheless, sim-
ulations indicated that this rate of overlap was no greater
than expected by random chance (see ‘Materials and Meth-
ods’ section), making it unlikely that substantial numbers
of undiscovered cancer lncRNAs remain to be discovered in
intergenic regions, at least with the datasets used here (Sup-
plementary Figure S1E).
In addition to known cancer lncRNAs, CLIO-TIM iden-
tifies 102 lncRNAs not previously linked to cancer (Fig-
ure 2C, dark grey) with a 3.8-fold enrichment of insertions
over intergenic genome. As will be shown below, these lncR-
NAs bear clinical and genomic features of functional can-
cer genes, and hence we decided to include them in CLC2.
It should be noted, however, that these ‘mutagenesis’ lncR-
NAs are labelled and hence may be removed by end users,
as desired.
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Figure 2. The CLIO-TIM pipeline identifies human cancer lncRNAs via functional evolutionary conservation. (A) Overview of transposon insertional
mutagenesis (TIM) method for identifying functional cancer genes. Engineered transposons carry bidirectional cassettes capable of either blocking or
upregulating gene transcription, depending on orientation. Transposons are introduced into a population of cells, where they integrate at random genomic
sites. The cells are injected into a mouse. In some cells, transposons will land in and perturb expression of a cancer gene (either tumour suppressor or
oncogene), giving rise to a tumour. DNA of tumour cells is sequenced to identify the exact location of the transposon insertion. Clusters of such insertions
are termed common insertion sites (CIS). (B) (Left) Schematic of the CLIO-TIM pipeline used here to identify human cancer genes using mouse CIS.
(Right) An example of a CLIO-TIM predicted cancer lncRNA, Gm36495. (C) The density of hCIS sites, normalized by gene length, in indicated classes
of lncRNAs. Statistical significance calculated by one-sided Fisher’s test. (D) Upper panels: Expression of LINC00570 RNA in response to inhibition
by CRISPRi (left) or ASOs (right) in n = 4 biological replicates. Lower panels: Measured populations of the same cells over time (n = 4 biological
replicates). Statistical significance calculated by Student’s t-test.
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To experimentally test the principal that human ortho-
logues of mouse cancer genes have a conserved function,
we selected LINC00570, identified by CLIO-TIM but never
previously been linked to cancer or cell proliferation. We
asked whether LINC00570 promotes cell growth in trans-
formed cells. We used RNA-sequencing data to search for
cell models where LINC00570 is expressed, and identified
robust expression in cervical carcinoma HeLa cells (Sup-
plementary Figure S2A). We designed three distinct ASOs
targeting the LINC00570 intron 2 and 3 and exon 3 of the
short isoform (intronic targeting ASOs are known to have
degradation efficiency comparable to exonic ones (55,56)).
Transfection of these ASOs led to strong and reproducible
decreases in steady state RNA levels in HeLa cells (Figure
2D). This resulted in significant decreases in cell prolifer-
ation rates (Figure 2D and Supplementary Figure S2B)).
We observed a similar effect through CRISPRi-mediated
inhibition of gene transcription by two independent guide
RNAs in HeLa (Figure 2D). To verify this qRT-PCR as-
say was measuring the correct cDNA, we isolated and se-
quenced the band, finding that it indeed originated from
the expected sequence (Supplementary Figure S2C). Orom
et al. reported that knockdown of LINC00570 (ncRNA-a5)
led to a reduction in nearby ROCK2 gene’s expression (54).
Surprisingly, we found that the expression of ROCK2 was
not detectably affected by LINC00570 knockdown (Supple-
mentary Figure S2D). In summary, LINC00570 predicted
by CLIO-TIM pipeline promotes growth of human cancer
cells, and is likely to have a deeply evolutionarily conserved
tumorigenic activity.
Enhanced cancer lncRNA catalogue integrating manual an-
notation, CRISPR screens and functional conservation
We next tallied the distinct lncRNAs in CLC3 and com-
pared them with existing cancer lncRNA databases. Fig-
ure 3A shows a breakdown of the composition of CLC2 in
terms of source, gene function and evidence strength. Where
possible, the genes are given a functional annotation, onco-
gene (og) or tumour suppressor (ts), according to evidence
for promoting or opposing cancer hallmarks. Oncogenes (n
= 275) quite considerably outnumber tumour suppressors
(n = 95), although it is not clear whether this reflects gen-
uine biology or an ascertainment bias relating to scientific
interest or technical issues. Smaller sets of lncRNAs are as-
sociated with both functions, or have no functional infor-
mation (those from TIM screens where the functions of hits
are ambiguous).
In terms of the quality of evidence sources, CLC2 rep-
resents a considerable improvement over the original CLC.
The fraction of lncRNAs with high quality in vivo evidence
(defined as functional validation in mouse models or muta-
genesis analysis) now represent 66% compared to 24% pre-
viously (Figure 3A and Supplementary Figure S3B). In to-
tal, the updated CLC2 comprises 33 cancer types (versus
29) and more lncRNAs are reported for every cancer sub-
type (Supplementary Figure S3A).
We were curious how much novelty the CLC2 gene
set brought to the known universe of cancer lncR-
NAs, as estimated from respected and longstanding can-
cer lncRNA collections (Figure 3B). Considering only
GENCODE-annotated lncRNA genes, CLC2 with 492 is
second only to Lnc2Cancer 3.0 (n = 688) in terms of
size (40). Lnc2Cancer and CLC2 share the greatest num-
ber of lncRNAs in common. However, Lnc2Cancer uses
looser inclusion criteria, including lncRNAs that are dif-
ferentially expressed in tumours without additional func-
tional evidence. The three remaining databases are smaller
(<200 genes).
The novel aspect of CLC2 to include lncRNAs from TIM
screens leads to the identification of 92 completely novel
genes, not detected in any other database (Figure 3B, inset).
Just 41 lncRNAs are common to all five databases (37–40).
In summary, CLC2 achieves large size without compromis-
ing on confidence, whilst also including numerous new can-
cer lncRNAs for the first time.
Unique genomic properties of CLC2 lncRNAs
Cancer genes, both protein-coding and not, display elevated
characteristics of essentiality and clinical importance com-
pared to other genes (4,18,57,58). In order to confirm their
quality as a resource, we next asked whether CLC2 lncR-
NAs, and the mutagenesis subset, display features expected
for cancer genes.
In the following analyses, we compared gene features of
selected lncRNAs to all other lncRNAs. Comparison of
gene sets can often be confounded by covariates, such as
gene length or gene expression, therefore where appropriate
we used control gene sets that were matched to CLC2 by ex-
pression (denoted ‘nonCLCmatched’) (Supplementary Fig-
ure S4A) and reported findings correcting for gene length
(Supplementary Figure S4B). We next tested for potentially
protein-coding transcripts amongst the CLC2 set. Overall,
only a small but non-negligible fraction (5.9%) of CLC2
genes indicated coding potential (Supplementary Figure
S4C). This highlights the general need for researchers to
exercise caution in interpreting the biotypes of annotated
lncRNAs and investigate their protein-coding status more
thoroughly where appropriate.
Evolutionary conservation and steady-state expression
are widely-used proxies for gene function (59–61). Using the
LnCompare tool (45), we find that the promoters and exons
of CLC2 genes display elevated evolutionary conservation
in mammalian and vertebrate phylogeny (Figure 4A) and el-
evated expression in cancer cell lines (Figure 4B). Strikingly
we observe a similar effect when considering the mutagen-
esis lncRNAs alone: their promoters are significantly more
conserved than expected by chance, and their expression is
an order of magnitude higher than other lncRNAs (Figure
4C and D).
Further, we found that CLC2 lncRNAs are enriched in
repetitive elements (Supplementary Figure S5A) and are
more likely to house a small RNA gene, possibly indicat-
ing that some act as precursor transcripts (Supplementary
Figure S5B). CLC2 lncRNAs also have non-random dis-
tributions of gene biotypes, being depleted for intergenic
class and enriched in divergent orientation to other genes
(Supplementary Figure S5C). This effect was not driven
by CRISPRi targets alone, since when the analysis was re-
peated without them, the same enrichment for divergent
lncRNAs was observed (P = 0.0038). We could observe an
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Figure 3. An overview of the CLC2 database and comparison with other cancer lncRNA databases. (A) The CLC2 database broken down by source,
function and evidence type. (B) Comparison of CLC2 to other leading cancer lncRNA databases. Only GENCODE-annotated lncRNAs are considered
here. Green box: Breakdown of 123 mutagenesis lncRNAs by database.
enrichment of CLC2 genes overlapping or within 10 kb dis-
tance of the TSS of the CGC genes compared to non-CGC
genes (Supplementary Figure S5D), suggesting cancer co-
functionalities for CLC and CGC genes.
In summary, CLC2 lncRNAs are significantly more
conserved and more expressed than expected by chance,
pointing to biological function. Mutagenesis lncRNAs
discovered by the CLIO-TIM also carry these fea-
tures, supports their designation as functional cancer
lncRNAs.
CLC2 lncRNAs display consistent tumour expression
changes and prognostic properties
Although gene expression was not a criterion for inclusion,
we would expect that CLC2 lncRNAs’ expression will be
altered in tumours. Furthermore, one might expect that the
nature of this alteration should vary with disease function:
oncogenes overexpressed, and tumour suppressors down-
regulated.
To test this, we analysed TCGA RNA-sequencing (RNA-
seq) data from 686 individual tumours with matched
healthy tissue (total n = 1372 analysed samples) in 20 dif-
ferent cancer types (Supplementary Figure S6A and B), and
classified every gene as either differentially expressed (in at
least one cancer subtype, with log2 fold change > 1 and
FDR < 0.05) or not. We found that CLC2 lncRNAs are 3.4-
fold more likely to be differentially expressed compared to
expression-matched lncRNAs (Figure 5A). LncRNAs from
each individual evidence source (literature, mutagenesis and
CRISPRi) behaved similarly, again supporting their inclu-
sion. Similar effects were found for pc-genes (Supplemen-
tary Figure S7A).
Next, we asked whether the direction of expression
change corresponds to gene function. Indeed, oncogenes
are enriched for overexpressed genes, whereas tumour sup-
pressors are enriched for downregulated genes, supporting
the functional labelling scheme (Figure 5B).
Cancer genes’ expression is often prognostic for patient
survival. By correlating expression to patient survival, we
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Figure 4. Features of functionality in CLC2 and mutagenesis lncRNAs. All data comes from LnCompare (45). In each panel, two gene sets are
compared––the test set (either all CLC2 genes, or mutagenesis subset alone), and the set of all other lncRNAs (GENCODE v24). y-axis: Log2 fold
difference between the means of gene sets. x-axis: false-discovery rate adjusted significance (FDR), calculated by Wilcoxon test. (A) Evolutionary conser-
vation for all CLC2, calculated by PhastCons. (B) Expression of all CLC2 in cell lines. (C) Evolutionary conservation for mutagenesis lncRNAs, calculated
by PhastCons. (D) Expression of mutagenesis lncRNAs in cell lines. For (A) and (C), ‘Promoter mean’ and ‘Exon mean’ indicate mean PhastCons scores
(7-vertebrate alignment) for those features, whilst ‘Exon-coverage’ indicates percent coverage by PhastCons elements. Promoters are defined as a window
of 200 nt centred on the transcription start site.
NAR Cancer, 2021, Vol. 3, No. 2 11
Figure 5. Clinical features of CLC2 lncRNAs. (A) The percent of indicated genes that are significantly differentially expressed in at least one tumour
type from the TCGA. Statistical significance calculated by one-sided Fisher’s test. (B) Here, only differentially expressed genes from (A) are considered.
LncRNAs with both tumour suppressor and oncogene labels are excluded. Remaining lncRNAs are divided by those that are up- or downregulated (positive
or negative fold change). Statistical significance calculated by one-sided Fisher’s test. (C) The density of germline cancer-associated SNPs is displayed. Only
SNPs falling in gene exons are counted, and are normalized to the total length of those exons. Statistical significance calculated by one-sided Fisher’s test.
(D) Examples of mutagenesis lncRNAs with an exonic cancer SNP. (E) Length-normalized overlap rate of copy number variants (CNVs) in lncRNA gene
span. Statistical significance calculated by one-sided Fisher’s test.
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found that the expression of 392 CLC2 lncRNAs correlated
to patient survival in at least one cancer type (Supplemen-
tary Figure S7C). When analysing the most significant cor-
relation of each CLC2 lncRNA compared to expression-
matched non-CLC lncRNAs, we find a weak but signifi-
cant enrichment (Supplementary Figure S7C), suggesting
that CLC2 lncRNAs can be prognostic for patient survival.
In summary, gene expression characteristics of CLC2
genes, and subsets from different evidence sources, support
their functional labels as oncogenes and tumour suppres-
sors and is more broadly consistent with their important
roles in tumorigenesis.
CLC2 lncRNAs are enriched with cancer genetic mutations
Cancer genes are characterized by a range of germline
and somatic mutations that lead to gain- or loss-of-
function. It follows that cancer lncRNAs should be en-
riched with germline single nucleotide polymorphisms
(SNPs) that have been linked to cancer predisposition (62).
We obtained 5331 germline cancer-associated SNPs from
GWAS (63) and mapped them to lncRNA and pc-gene ex-
ons, calculating a density score that normalizes for exon
length (Supplementary Figure S4B). As expected, exons
of known cancer pc-genes are >2-fold enriched in can-
cer SNPs (Supplementary Figure S7B). When performing
the same analysis with CLC2 lncRNAs, one observes an
even more pronounced enrichment of 4.0-fold when com-
paring to expression-matched non-CLC lncRNAs (Fig-
ure 5C). Once again, the lncRNAs from each evidence
source individually show enrichment for cancer SNPs >2-
fold (Figure 5C). Three mutagenesis lncRNAs, namely
miR143HG/CARMN, LINC00511 and LINC01488, carry
an exonic cancer SNP (Figure 5D).
CLC2 exons containing a cancer SNP are less con-
served than CLC2 exons overall, and display a conservation
level comparable to non-CLC exons (Supplementary Figure
S7D). This is consistent with previous reports demonstrat-
ing that SNPs tend to occur in regions of lower than average
evolutionary conservation (64).
Cancer genes are also frequently the subject of large-scale
somatic mutations, or copy number variants (CNVs). Using
a collection of CNV data from LncVar (47), we calculated
the gene-span length-normalized coverage of lncRNAs by
CNVs. CLC2 lncRNAs are enriched for CNVs compared
to all lncRNAs (Figure 5E).
All information of the lncRNAs in the CLC2 with
the corresponding cancer function, evidence level, analysis
method and cancer types can be found in the Supplemen-
tary Table S1. The Supplementary Table S2 can be used to
filter lncRNAs based on their reported cancer associated
functionalities.
In summary, CLC2 lncRNAs and their subsets display
germline and somatic mutational patterns consistent with
known oncogenes and tumour suppressors
DISCUSSION
We have presented the CLC2, an expanded collection of
lncRNAs with functional roles in cancer. CLC2 is distin-
guished from other resources by several key features. All its
constituent lncRNAs have strong evidence for functional
cancer roles (and not merely differential expression), pro-
viding for lowest possible false positive rates. All CLC2
lncRNAs are included in the gold-standard GENCODE
annotation, permitting smooth interoperability with almost
all public genomics projects and resources (12). The major-
ity of CLC2 entries are accompanied by functional labels
(oncogene/tumour suppressor), enabling one to link func-
tion to other observable features. Finally, we utilize trans-
poson insertional mutagenesis (TIM) datasets for the first
time to discover 102 ‘mutagenesis’ lncRNAs, of which 92
are completely novel. In spite of strict inclusion criteria,
CLC2 is amongst the largest available cancer lncRNA col-
lections. Overall, CLC2 makes a valuable addition to the
present landscape of cancer lncRNA resources.
A key novelty of CLC2 is its use of automated
gene curation based on functional evolutionary conserva-
tion, as inferred from TIM. This responds to the chal-
lenge from the rapid growth of scientific literature, which
makes manual curation increasingly impractical. Other
high-throughput/automated methods like CRISPR pooled
screening, text mining and machine learning will also be
important, although it will be necessary to vet the qual-
ity of such predictions prior to inclusion. Here we showed
one way approach for this, by assessing the TIM gene set
across a range of genomic and clinical features. The fact that
the ‘mutagenesis’ lncRNA set display rates of (i) nucleotide
conservation, (ii) expression, (iii) tumour differential ex-
pression, (iv) germline cancer polymorphisms and (v) tu-
mour mutations similar to that of gold-standard literature-
curated lncRNAs, coupled to thorough experimental val-
idation of one novel prediction (LINC00570), is powerful
support for TIM and functional evolutionary conservation
as means for new cancer lncRNA discovery.
It might be argued that hits from TIM sites could be
false positives that act via DNA elements (for example,
enhancers) that, by coincidence, overlap a non-functional
lncRNA. Whilst certainly likely to occur in some cases, it
would nevertheless appear unlikely to explain the majority,
in light of the features listed above, plus the observation
that TIM sites are highly enriched in independently vali-
dated literature-curated lncRNAs (which act via RNA) in-
cluding NEAT1, LINC-PINT and PVT1 (42). In spite of
this, we recognize that some colleagues may ascribe lower
confidence to novel ‘mutagenesis’ lncRNAs in CLC2. For
this reason, the CLC2 data table is organized to facilitate
filtering by source, enabling users to extract only the 375
literature-supported cases, or indeed any other subset based
on source, evidence or function as desired.
Apart from its usefulness as a resource, this study has
enabled some important conceptual insights. Firstly, we
have replicated our previous finding that cancer lncRNAs
are distinguished by signatures of functionality, as inferred
from evolutionary nucleotide conservation and expression.
These features were originally linked to protein-coding
cancer genes (57,58), but are also utilized as markers for
lncRNA functionality (42,65). Moreover, we extended this
approach to clinical features, by showing that curated can-
cer lncRNAs are dramatically more likely to be differen-
tially expressed in tumours, suffer copy number alteration,
or carry a germline predisposition SNP. In the latter case,
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this rate even exceeds cancer driver pc-genes. We also could
demonstrate that changes in gene expression in tumours
are linked to function: oncogenes tend to be overexpressed,
whilst tumour-suppressors tend to be repressed. Finally, the
demonstration that cancer lncRNAs can be predicted on
the basis of orthology to a TIM hit in mouse, lends power-
ful support to the notion that there is widespread functional
evolutionary conservation of lncRNAs in networks related
to cell growth and transformation.
LINC00570 is a new functional cancer lncRNA pre-
dicted by CLIO-TIM. The gene was previously discovered
by Orom and colleagues, as a cis-activating enhancer-like
RNA named ncRNA-a5 (54). That and a subsequent study
showed that perturbation by siRNA transfection affects the
expression of the nearby pc-gene ROCK2 in HeLa. How-
ever, these studies did not investigate the effect on cell prolif-
eration. We here show by means of two independent pertur-
bations, that LINC00570 promotes proliferation of HeLa
cells. These findings make LINC00570 a potential therapeu-
tic target for follow up.
Intriguingly, amongst the novel mutagenesis lncRNAs
identified by CLIO-TIM are genes previously linked to
other diseases. miR143HG/CARMEN1 (CARMN) was
shown to regulate cardiac specification and differentiation
in mouse and human hearts (66). In addition to being a TIM
target, CARMEN1 also contains a germline cancer SNP
correlating with the risk of developing lung cancer (67),
adding further weight to the notion that it also plays a role
in oncogenesis. Similarly, DGCR5, is located in the DiGe-
orge critical locus and has been linked to neurodevelopment
and neurodegeneration (68), and was recently implicated as
a tumour suppressor in prostate cancer (69). These results
raise the possibility that developmental lncRNAs can also
play roles in cancer.
In summary, CLC2 establishes a new benchmark for can-
cer lncRNA resources. We hope this dataset will enable a
wide range of studies, from bioinformatic identification of
new disease genes, to developing a new generation of cancer
therapeutics with anti-lncRNA ASOs (70).
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